Table 2.
Treatment of CKD rat model with ZnO-NP and SPL results in improvement of renal function.
| Variables (mean ± SD) | Control | CKD | SPL | ZnO-NPs | SPL + ZnO-NPs |
|---|---|---|---|---|---|
| Serum creatinine (mg/dL) | 0.68 ± 0.19 | 4.09 ± 0.9a | 2.74 ± 0.29ab | 1.53 ± 0.36abc | 0.8 ± 0.16bc |
| BUN (mg/dL) | 18.99 ± 1.95 | 54.36 ± 6.99a | 41.98 ± 6.73ab | 32 ± 7.05abc | 21.4 ± 2.33abcd |
| Crcl (mL/min) | 1.44 ± 0.16 | 0.54 ± 0.17a | 0.83 ± 0.09ab | 0.93 ± 0.11ab | 1.16 ± 0.12abcd |
| Microalbuminuria (mg/24 h) | 20.69 ± 1.6 | 96.8 ± 13.22a | 68.9 ± 10.2ab | 52.55 ± 7.74abc | 35.54 ± 5.45abcd |
Notes: Where control group: normal group, CKD group: adenine sulfate (positive control group), SPL group: SPL + adenine sulfate, ZnO-NPs group: ZnO-NPs + adenine sulfate, SPL + ZnO-NPs group: SPL + ZnO-NPs + adenine sulfate.
Significant difference compared to corresponding acontrol group, bCKD group,cSPL group, dZnO-NPs group at p < 0.05 by ANOVA and Tukey test.